Gyre Therapeutics (GYRE) Total Liabilities (2010 - 2026)
Gyre Therapeutics (GYRE) reported Total Liabilities of $25.0 million for Q1 2026, down 1.8% year-over-year from $25.5 million in Q1 2025, and up 4.95% on a QoQ basis from $23.8 million in Q4 2025.
Gyre Therapeutics (GYRE) has 17 years of Total Liabilities data on file, last reported at $25.0 million in Q1 2026.
- Quarterly Total Liabilities fell 1.8% year-over-year to $25.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.0 million (down 1.8% YoY) and the FY2025 annual result came in at $23.8 million, down 11.68% from the prior year.
- Total Liabilities advanced to $25.0 million in Q1 2026 per GYRE's latest filing, from $23.8 million in the prior quarter.
- Across five years, Total Liabilities topped out at $38.1 million in Q4 2023 and bottomed at $1.6 million in Q3 2022.
- The 5-year median for Total Liabilities is $23.2 million (2025), against an average of $19.4 million.
- The widest annual swing landed in 2022, when Total Liabilities tumbled 90.76%; it then surged 315.17% in 2024.
- Tracing GYRE's Total Liabilities over 5 years: stood at $12.5 million in 2022, then soared by 203.65% to $38.1 million in 2023, then dropped by 29.06% to $27.0 million in 2024, then retreated by 11.68% to $23.8 million in 2025, then grew by 4.95% to $25.0 million in 2026.
- Per Business Quant, the three latest GYRE Total Liabilities figures stand at $25.0 million (Q1 2026), $23.8 million (Q4 2025), and $22.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | 25.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.03 Mn |
| Dec 31, 2025 | 23.85 Mn |
| Sep 30, 2025 | 21.97 Mn |
| Jun 30, 2025 | 23.20 Mn |
| Mar 31, 2025 | 25.49 Mn |
| Dec 31, 2024 | 27.00 Mn |
| Sep 30, 2024 | 26.77 Mn |
| Jun 30, 2024 | 27.58 Mn |
| Mar 31, 2024 | 33.24 Mn |
| Dec 31, 2023 | 38.07 Mn |
| Sep 30, 2023 | 6.45 Mn |
| Jun 30, 2023 | 7.40 Mn |
| Mar 31, 2023 | 11.39 Mn |
| Dec 31, 2022 | 12.54 Mn |
| Sep 30, 2022 | 1.64 Mn |
| Jun 30, 2022 | 4.31 Mn |
| Mar 31, 2022 | 13.19 Mn |
| Dec 31, 2021 | 14.57 Mn |
| Sep 30, 2021 | 17.80 Mn |
| Jun 30, 2021 | 16.62 Mn |
| Mar 31, 2021 | 14.99 Mn |
| Dec 31, 2020 | 18.78 Mn |
| Sep 30, 2020 | 17.75 Mn |
| Jun 30, 2020 | 14.72 Mn |
| Mar 31, 2020 | 13.04 Mn |
| Dec 31, 2019 | 30.22 Mn |
| Sep 30, 2019 | 10.52 Mn |
| Jun 30, 2019 | 7.76 Mn |
| Mar 31, 2019 | 6.06 Mn |
| Dec 31, 2018 | 4.98 Mn |
| Sep 30, 2018 | 3.47 Mn |
| Jun 30, 2018 | 2.58 Mn |
| Mar 31, 2018 | 3.04 Mn |
| Dec 31, 2017 | 8.74 Mn |
| Sep 30, 2017 | 9.51 Mn |
| Jun 30, 2017 | 9.28 Mn |
| Mar 31, 2017 | 15.22 Mn |
| Dec 31, 2016 | 22.02 Mn |
| Sep 30, 2016 | 32.01 Mn |
| Jun 30, 2016 | 33.74 Mn |
| Mar 31, 2016 | 33.55 Mn |
| Dec 31, 2015 | 38.10 Mn |
| Sep 30, 2015 | 38.31 Mn |
| Jun 30, 2015 | 1.64 Mn |
| Mar 31, 2015 | 3.90 Mn |
| Dec 31, 2014 | 3.46 Mn |
| Sep 30, 2014 | 3.21 Mn |
| Jun 30, 2014 | 7.50 Mn |
| Mar 31, 2014 | 10.01 Mn |
| Dec 31, 2013 | 11.26 Mn |
| Sep 30, 2013 | 11.11 Mn |
| Jun 30, 2013 | 9.31 Mn |
| Mar 31, 2013 | 9.29 Mn |
| Dec 31, 2012 | 13.66 Mn |
| Sep 30, 2012 | 12.93 Mn |
| Jun 30, 2012 | 16.26 Mn |
| Mar 31, 2012 | 52.40 Mn |
| Dec 31, 2011 | 83.84 Mn |
| Sep 30, 2011 | 97.73 Mn |
| Jun 30, 2011 | 110.92 Mn |
| Dec 31, 2010 | 170.94 Mn |